Feature / NICE update

NICE published the following guidance in May:

Clinical guidance

CG 160 Feverish illness in children: assessment and initial management in children younger than five years – A costing statement has been produced for this guideline because it is considered that implementing the recommendations will not have a significant resource impact.

Technology guidance

TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion – The manufacturer of ranibizumab has agreed a patient access scheme with the Department of Health that makes ranibizumab available with a discount. The level of the discount is commercial in confidence. Based on the list price, the annual cost associated with implementing this recommendation is estimated as £99,000 for a population of 100,000 based on the standard assumptions in the model. The costs are based on the incident population and full uptake. ? TA 284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer – The guidance on bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer is unlikely to result in a significant change in resource use in the NHS. Bevacizumab in combination with paclitaxel and carboplatin is not recommended for first-line treatment of advanced ovarian cancer.

TA 285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer – The guidance on bevacizumab for the treatment of recurrent advanced ovarian cancer is unlikely to result in a significant change in resource use in the NHS. Bevacizumab in combination with gemcitabine and carboplatin is not recommended within its marketing authorisation – that is, for treating people with the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.

Public health guidance

PH 44 Physical activity: brief advice for adults in primary care – Where the additional requirement cannot be managed within existing resources, it is estimated that the annual cost impact of the guidance is anticipated to be £10,600 per 100,000 population. The majority of this is due to brief physical activity advice delivered in a separate appointment.

NICE update was prepared by Stephen Brookfield, senior costing analyst at NICE